ArticleEndocrine pathology2006
Immunohistochemical separation of follicular variant of papillary thyroid carcinoma from follicular adenoma.
Article in Endocrine pathology, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Galectin-3 Performance in Histologic a Cytologic Assessment of Thyroid Nodules: A Systematic Review and Meta-Analysis.International journal of molecular sciences · 2017Pooled it
- Defining the value of CD56, CK19, Galectin 3 and HBME-1 in diagnosis of follicular cell derived lesions of thyroid with systematic review of literature.Diagnostic pathology · 2015Pooled it
- Expression of CK-19, galectin-3 and HBME-1 in the differentiation of thyroid lesions: systematic review and diagnostic meta-analysis.Diagnostic pathology · 2012Pooled it
- A Machine Learning-Based Model for Preoperative Assessment and Malignancy Prediction in Patients with Atypia of Undetermined Significance Thyroid Nodules.Journal of clinical medicine · 2024Article
- Article
- HBME1 and CK19 expression in non-invasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP) vs other follicular patterned thyroid lesions.World journal of surgical oncology · 2021Article
- Identification of potential novel biomarkers to differentiate malignant thyroid nodules with cytological indeterminate.BMC cancer · 2020Article
- The Potential Diagnostic Utility of TROP-2 in Thyroid Neoplasms.Applied immunohistochemistry & molecular morphology : AIMM · 2017Article
- Papillary thyroid cancer located in malignant struma ovarii with omentum metastasis: a case report and review of the literature.World journal of surgical oncology · 2016Review
- In Situ Hybridization Analysis of miR-146b-5p and miR-21 in Thyroid Nodules: Diagnostic Implications.Endocrine pathology · 2015Article
- Comparison of microarray expression profiles between follicular variant of papillary thyroid carcinomas and follicular adenomas of the thyroid.BMC genomics · 2015Article
- Cytokeratin19 expression discriminates papillary thyroid carcinoma from other thyroid lesions and predicts its aggressive behavior.Medical oncology (Northwood, London, England) · 2013Article
- Diagnostic utility of galectin-3 in thyroid cancer.The American journal of pathology · 2010Review
- Utility of immunohistochemical markers in differentiating benign from malignant follicular-derived thyroid nodules.Diagnostic pathology · 2010Article
- Thyroid tumours of uncertain malignant potential: frequency and diagnostic reproducibility.Virchows Archiv : an international journal of pathology · 2009Article
- A score based on microscopic criteria proposed for analysis of papillary carcinoma of the thyroid.Virchows Archiv : an international journal of pathology · 2008Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The accurate diagnosis of differentiated thyroid tumors is very important for clinical management of patients. The histopathological distinction between some types of differentiated thyroid tumors can be very difficult even for experienced pathologists. We used immunohistochemical markers from published data obtained from DNA expression profiling, tissue microarray analysis, and immunohistochemistry to analyze a series of 157 thyroid tumors and 5 normal thyroids. These analyses showed that several antibodies were useful in distinguishing follicular adenomas from follicular variant of papillary thyroid carcinomas including HBME-1, CITED1, galectin-3, cytokeratin 19, and S100A4 (p < 0.0001). A combination of markers consisting of a panel of HBME-1, galectin-3, and CK19 or a panel of HBME-1, CITED1, and galectin-3 was usually most effective in distinguishing follicular adenoma from follicular variant of papillary thyroid carcinoma. Because individual tumors may not express some of these markers, the use of a panel of antibodies is recommended. These results indicate that some individual antibodies or a panel of antibodies combined with histopathological analysis can be useful in separating follicular adenoma (FA) from follicular variant of papillary thyroid carcinoma (FVPTC).
Indexed as
Identifiers
17308358What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.